Format

Send to

Choose Destination
Clin Infect Dis. 2020 Feb 28. pii: ciaa061. doi: 10.1093/cid/ciaa061. [Epub ahead of print]

Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.

Author information

1
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
2
US Public Health Service Commissioned Corps, Rockville, Maryland, USA.
3
Epidemiology Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
4
Vizient, Irving, Texas, USA.
5
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
6
Hospital Epidemiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
7
Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, National Cancer Institute Campus at Frederick, Frederick, Maryland, USA.
8
Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
9
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
10
Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.
11
Program of Comparative Effectiveness Methodology, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.
12
School of Medicine, Duke University, Durham, North Carolina, USA.

Abstract

BACKGROUND:

Ceftazidime-avibactam has in vitro activity against some carbapenem-resistant gram-negative infections (GNIs), and therefore may be a useful alternative to more toxic antibiotics such as colistin. Understanding ceftazidime-avibactam uptake and usage patterns would inform hospital formularies, stewardship, and antibiotic development.

METHODS:

A retrospective cohort study assessed inpatient encounters in the Vizient database. Ceftazidime-avibactam and colistin administrations were categorized into presumed empiric (3 consecutive days of therapy or less with qualifying exclusions) versus targeted therapy (≥4 consecutive days of therapy) for presumed carbapenem-resistant GNIs. Quarterly percentage change (QPC) using modified Poisson regression and relative change in frequency of targeted ceftazidime-avibactam to colistin encounters was calculated. Factors associated with preferentially receiving targeted ceftazidime-avibactam versus colistin were identified using generalized estimating equations.

RESULTS:

Between 2015 quarter (q) 1 and 2017q4, ceftazidime-avibactam was administered 21 215 times across 1901 encounters. Inpatient prescriptions for ceftazidime-avibactam increased from 0.44/10 000 hospitalizations in 2015q1 to 7.7/10 000 in 2017q4 (QPC, +11%; 95% CI, 10-13%; P < .01), while conversely colistin prescriptions decreased quarterly by 5% (95% CI, 4-6%; P < .01). Ceftazidime-avibactam therapy was categorized as empiric 25% of the time, targeted 65% of the time, and indeterminate 10% of the time. Patients with chronic kidney disease were twice as likely to receive targeted ceftazidime-avibactam versus colistin (RR, 2.02; 95% CI, 1.82-2.25), whereas those on dialysis were less likely to receive ceftazidime-avibactam than colistin (RR, 0.71; 95% CI, .61-.83).

CONCLUSIONS:

Since approval in 2015, ceftazidime-avibactam use has grown for presumed carbapenem-resistant GNIs, while colistin has correspondingly declined. Renal function drove the choice between ceftazidime-avibactam and colistin as targeted therapy.

KEYWORDS:

carbapenem resistance; ceftazidime-avibactam; novel beta-lactamase inhibitors; ram-negative resistance

PMID:
32107536
DOI:
10.1093/cid/ciaa061

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center